ChiCTR2400095062 版本V1.0 版本创建时间2024/12/31 17:23:19 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2400095062 

最近更新日期:

Date of Last Refreshed on:

2024-12-31 17:23:06 

注册时间:

Date of Registration:

2024-12-31 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

环泊酚对OSAHS患者气管插管应激反应和全麻苏醒期躁动的影响

Public title:

The effect of ciprofol on tracheal intubation stress response and emergence agitation in OSAHS patients

注册题目简写:

English Acronym:

研究课题的正式科学名称:

环泊酚对OSAHS患者气管插管应激反应和全麻苏醒期躁动的影响

Scientific title:

The effect of ciprofol on tracheal intubation stress response and emergence agitation in OSAHS patients

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

李仁虎 

研究负责人:

李仁虎 

Applicant:

Renhu Li 

Study leader:

Renhu Li 

申请注册联系人电话:

Applicant telephone:

+86 139 6624 1616

研究负责人电话:

Study leader's
telephone:

+86 139 6624 1616

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

lirenhu2008@163.com

研究负责人电子邮件:

Study leader's E-mail:

lirenhu2008@163.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

安徽省六安市皖西路21号

研究负责人通讯地址:

安徽省六安市皖西路21号

Applicant address:

No.21 Wanxi Road, Lu 'an City, Anhui Province

Study leader's address:

No.21 Wanxi Road, Lu 'an City, Anhui Province

申请注册联系人邮政编码:

Applicant postcode:

237005

研究负责人邮政编码:

Study leader's postcode:

237005

申请人所在单位:

安徽医科大学附属六安医院

Applicant's institution:

Lu 'an Hospital Affiliated to Anhui Medical University

研究负责人所在单位:

安徽医科大学附属六安医院

Affiliation of the Leader:

Lu 'an Hospital Affiliated to Anhui Medical University

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

2024LL027

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

六安市人民医院伦理委员会

Name of the ethic committee:

Ethics Committee of Lu'an People's Hospital

伦理委员会批准日期:

Date of approved by ethic committee:

2024-12-15 00:00:00

伦理委员会联系人:

赵勇

Contact Name of the ethic committee:

Yong Zhao

伦理委员会联系地址:

安徽省六安市皖西路21号

Contact Address of the ethic committee:

No.21 Wanxi Road, Lu 'an City, Anhui Province

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 564 333 8627

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

安徽医科大学附属六安医院

Primary sponsor:

Lu 'an Hospital Affiliated to Anhui Medical University

研究实施负责(组长)单位地址:

安徽省六安市皖西路21号

Primary sponsor's address:

No.21 Wanxi Road, Lu 'an City, Anhui Province

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

安徽省

市(区县):

六安市

Country:

China

Province:

Anhui Province

City:

Lu'an city

单位(医院):

安徽医科大学附属六安医院

具体地址:

安徽省六安市皖西路21号

Institution
hospital:

Lu 'an Hospital Affiliated to Anhui Medical University

Address:

No.21 Wanxi Road, Lu 'an City, Anhui Province

经费或物资来源:

2023年度六安市科技计划项目

Source(s) of funding:

2023 Lu 'an Science and technology plan project

研究疾病:

阻塞性睡眠呼吸暂停低通气综合征  

Target disease:

Obstructive Sleep Apnea-Hypopnea Syndrome

研究疾病代码:

Target disease code:

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

其它 

Study phase:

N/A

研究设计:

随机平行对照 

Study design:

Parallel 

研究目的:

探讨环泊酚,丙泊酚,瑞马唑仑这三种药物对OSAHS患者气管插管应激反应和全麻苏醒期躁动的影响  

Objectives of Study:

To investigate the effects of ciprofol, propofol and remimazolam on the stress response of endotracheal intubation and agitation during the awakening period of general anesthesia in patients with OSAHS

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

ASAI-III级,男女不限,年龄18~64岁,我院择期行UPPP术的OSAHS患者。

Inclusion criteria

ASAI-III, male or female, age 18~64 years old, OSAHS patients who undergo elective UPPP surgery in our hospital.

排除标准:

1.对研究药物过敏者; 2.精神分裂症及严重抑郁状态者。 3.重症肌无力者; 4.合并呼吸系统疾病(哮喘、气道高反应、慢性阻塞性肺疾病急性发作)者; 5.合并心血管疾病(急性心梗、心衰、严重心律失常和房室传导阻滞等)者; 6.合并其他严重系统疾病者; 7.重度肥胖,BMI>=35者。

Exclusion criteria:

1. Those who are allergic to the study drug; 2. People with schizophrenia and severe depressive state. 3. Myasthenia gravis; 4. Patients with respiratory diseases (asthma, airway hyperresponsiveness, acute exacerbation of chronic obstructive pulmonary disease); 5. Patients with cardiovascular diseases (acute myocardial infarction, heart failure, severe arrhythmia and atrioventricular block, etc.); 6. Patients with other serious systemic diseases; 7. Those with severe obesity and BMI >=35.

研究实施时间:

Study execute time:

From 2025-01-01 00:00:00 To 2025-12-31 00:00:00  

征募观察对象时间:

Recruiting time:

From 2025-01-01 00:00:00 To 2025-12-30 00:00:00

干预措施:

Interventions:

组别:

环泊酚组

样本量:

30

Group:

Cyclopofol group

Sample size:

干预措施:

麻醉诱导:静注环泊酚;麻醉维持:泵注环泊酚

干预措施代码:

Intervention:

Anesthesia induction: intravenous cyclopofol; Anesthesia maintenance: Pump cyclopofol

Intervention code:

组别:

丙泊酚组

样本量:

30

Group:

Propofol group

Sample size:

干预措施:

麻醉诱导:静注丙泊酚;麻醉维持:泵注丙泊酚

干预措施代码:

Intervention:

Anesthesia induction: intravenous injection of propofol; Anesthesia maintenance: pump propofol

Intervention code:

组别:

瑞马唑仑组

样本量:

30

Group:

Remimazolam group

Sample size:

干预措施:

麻醉诱导:静注瑞马唑仑;麻醉维持:泵注瑞马唑仑

干预措施代码:

Intervention:

Anesthesia induction: intravenous remimazolam; Anesthesia maintenance: Pump remimazolam

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

安徽省 

市(区县):

六安市 

Country:

China

Province:

Anhui Province

City:

Lu'an City

单位(医院):

安徽医科大学附属六安医院 

单位级别:

三甲 

Institution
hospital:

Lu 'an Hospital Affiliated to Anhui Medical University

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

气管插管应激反应

指标类型:

主要指标

Outcome:

Tracheal intubation stress reaction

Type:

Primary indicator

测量时间点:

全身麻醉实施时

测量方法:

Measure time point of outcome:

When general anesthesia is administered

Measure method:

指标中文名:

全麻苏醒期躁动

指标类型:

主要指标

Outcome:

Emergence agitation

Type:

Primary indicator

测量时间点:

全麻苏醒期

测量方法:

躁动评分量表

Measure time point of outcome:

Awakening period from general anesthesia

Measure method:

指标中文名:

术后认知功能障碍

指标类型:

次要指标

Outcome:

Postoperative cognitive dysfunction

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

术中知晓

指标类型:

次要指标

Outcome:

Intraoperative awareness

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

注射疼

指标类型:

次要指标

Outcome:

Injection pain

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

术后恶心呕吐

指标类型:

次要指标

Outcome:

Postoperative nausea and vomiting

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

过敏

指标类型:

附加指标

Outcome:

Allergy

Type:

Additional indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

血液

组织:

Sample Name:

Blood

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age 18 years
最大 Max age 64 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

由另一名麻醉医生用随机数字表法产生随机序列

Randomization Procedure (please state who generates the random number sequence and by what method):

The random sequence was generated by another anesthesiologist using a random number table method.

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

双盲,对研究参与者和研究者设盲

Blinding:

Double-blind, blinding the study participants and investigators

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

否No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

None

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

CRF;EDC

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

CRF;EDC

数据与安全监察委员会:

Data and Safety Monitoring Committee:

暂未确定/Not yet

注册人:

Name of Registration:

 2024-12-31 17:23:06